Research peptides are not approved for human use in most countries including India. This page is for educational purposes only. Consult a physician before use.
What is SLU-PP-332?
SLU-PP-332 is a synthetic small molecule (not strictly a peptide) pan-agonist of estrogen-related receptors α, β, and γ (ERRα/β/γ). It was developed by Thomas Burris and colleagues at Saint Louis University (hence "SLU") and published in a landmark 2023 paper that generated significant media attention for demonstrating endurance-like effects in sedentary mice.
Despite often being categorized with research peptides in biohacking communities, SLU-PP-332 is technically a small molecule drug — a synthetic compound designed to activate specific transcription factor receptors. This distinction matters for pharmacokinetics and regulatory classification.
The ERR Mechanism: Exercise as Gene Expression
Understanding SLU-PP-332 requires understanding what estrogen-related receptors do:
- ERRs are orphan nuclear receptors — transcription factors that control gene expression but have no known endogenous ligand in the traditional sense
- ERRα is the master regulator of mitochondrial biogenesis and oxidative metabolism — it controls hundreds of genes involved in fatty acid oxidation, TCA cycle, and mitochondrial electron transport
- ERRγ is particularly interesting for exercise biology — it controls the shift from glycolytic (fast-twitch) to oxidative (slow-twitch) muscle fiber composition that characterizes endurance-trained athletes
- When you do endurance exercise, ERRα and ERRγ activation is part of the cascade that produces mitochondrial biogenesis and metabolic adaptation
SLU-PP-332 activates all three ERRs simultaneously, triggering the downstream gene expression program associated with endurance training — without the mechanical stimulation of exercise itself.
The Preclinical Results
The Burris lab published striking results in the 2023 paper:
- Sedentary mice treated with SLU-PP-332 had significantly improved endurance capacity on treadmill testing
- Improved mitochondrial density and oxidative enzyme activity in skeletal muscle
- Shift toward oxidative (type I) muscle fiber composition
- Improved metabolic parameters including insulin sensitivity and reduced fat mass
- Reduced cardiac fibrosis in a heart failure model
The results were reproducible and mechanistically consistent with ERR activation. The media called it "exercise in a pill" — a characterization that, while capturing the imagination, significantly overstates where the science currently stands.
There is zero human data on SLU-PP-332. No pharmacokinetic studies in humans. No safety studies in humans. No dose-finding in humans. No efficacy studies in humans. The impressive mouse data is a starting point for drug development — not a basis for human use. Anyone using SLU-PP-332 is operating without any human evidence whatsoever.
SLU-PP-332 vs Other Exercise Mimetics
| Compound | Mechanism | Type | Human Data | Current Status |
|---|---|---|---|---|
| SLU-PP-332 | ERRα/β/γ pan-agonism | Small molecule | None | Preclinical research |
| MOTS-c | AMPK activation via folate cycle | Mitochondrial peptide | None (intervention) | Preclinical research |
| AICAR | Direct AMPK activation | Nucleoside analog | Limited metabolic studies | Research; WADA banned |
| GW501516 (Cardarine) | PPARδ agonism | Small molecule | Limited trials — discontinued | Abandoned due to cancer risk in animals |
Where the Research is Heading
SLU-PP-332 and related ERR agonists are being developed as potential pharmaceutical treatments for:
- Metabolic syndrome and type 2 diabetes — improving insulin sensitivity through metabolic reprogramming
- Sarcopenia — preventing muscle loss in aging through oxidative fiber preservation
- Heart failure — the cardiac ERRγ data is interesting for dilated cardiomyopathy
- Obesity — increased energy expenditure through metabolic shift
This is legitimate pharmaceutical research. The problem is the timeline: drug development typically takes 10–15 years from preclinical to approval. The internet biohacking community is trying to use these compounds years before safety and dosing are established.
Frequently Asked Questions
What is an exercise mimetic compound?
An exercise mimetic activates some biological pathways triggered by exercise without requiring physical activity. Exercise stimulates hundreds of molecular pathways — exercise mimetics target specific key transcriptional regulators (like ERR or AMPK) to activate downstream metabolic adaptations similar to endurance training.
SLU-PP-332 vs MOTS-c — which is better?
They use completely different mechanisms. SLU-PP-332 activates ERR transcription factors. MOTS-c activates AMPK. Neither has human trial data. Neither is appropriate for use outside controlled research. Theoretically complementary as their mechanisms converge on similar metabolic outcomes through different routes.
Is there human data for SLU-PP-332?
No. All SLU-PP-332 data is from animal studies. There are no human pharmacokinetic data, no human safety data, and no human efficacy trials. The impressive preclinical results generated significant media attention but should not be extrapolated to human use without clinical validation.
How does SLU-PP-332 work mechanically?
SLU-PP-332 is a pan-agonist of estrogen-related receptors α, β, and γ. ERRs are transcription factors controlling hundreds of genes involved in mitochondrial biogenesis, fatty acid oxidation, and muscle fiber type composition. Activating ERRs triggers a gene expression cascade mirroring endurance training adaptations.